Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | |
Any treatment-related AE | 58 (96.7%) | 34 (56.7%) | 4 (6.7%) | 1 (1.7%) |
Leukocytopenia | 22 (36.7%) | 26 (43.3%) | 4 (6.7%) | 0 |
Thrombocytopenia | 31 (51.7%) | 4 (6.7%) | 0 | 0 |
Anemia | 47 (78.3%) | 3 (5.0%) | 1 (1.7%) | 0 |
Increased AST/ALT | 23 (38.3%) | 2 (3.3%) | 0 | 0 |
Increased γ-GT | 9 (15.0%) | 0 | 0 | 0 |
Increased LDH/AKP | 37 (61.7%) | 0 | 0 | 0 |
Nausea | 10 (16.7%) | 0 | 0 | 0 |
Vomiting | 5 (8.3%) | 0 | 0 | 0 |
Diarrhea | 4 (6.7%) | 0 | 0 | 0 |
Constipation | 6 (10.0%) | 0 | 0 | 0 |
Asthenia or fatigue | 18 (30.0%) | 0 | 0 | 0 |
Fever | 6 (10.0%) | 2 (3.3%) | 0 | 0 |
Alopecia | 42 (70.0%) | 0 | 0 | 0 |
Blurred vision | 3 (5.0%) | 1 (1.7%) | 0 | 0 |
Neurotoxicity | 3 (5.0%) | 0 | 0 | 0 |
Proteinuria | 5 (8.3%) | 0 | 0 | 0 |
Urinary infection | 2 (3.3%) | 0 | 0 | 0 |
Cutaneous capillary proliferation | 16 (26.7%) | 0 | 0 | 0 |
Rash maculopapular | 10 (16.7%) | 0 | 0 | 0 |
Pruritus | 10 (16.7%) | 0 | 0 | 0 |
Pneumonia | 1 (1.7%) | 2 (3.3%) | 0 | 1 (1.7%) |
Hypothyroidism | 4 (6.7%) | 0 | 0 | 0 |
Hyperthyroidism | 1 (1.7%) | 0 | 0 | 0 |
AKP, alkline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GT, glutamyltranspeptidase; LDH, lactate dehydrogenase.